全文获取类型
收费全文 | 41913篇 |
免费 | 2916篇 |
国内免费 | 100篇 |
专业分类
耳鼻咽喉 | 464篇 |
儿科学 | 1561篇 |
妇产科学 | 1089篇 |
基础医学 | 5103篇 |
口腔科学 | 485篇 |
临床医学 | 6889篇 |
内科学 | 7184篇 |
皮肤病学 | 591篇 |
神经病学 | 3963篇 |
特种医学 | 891篇 |
外国民族医学 | 1篇 |
外科学 | 4214篇 |
综合类 | 440篇 |
一般理论 | 50篇 |
预防医学 | 5826篇 |
眼科学 | 438篇 |
药学 | 2602篇 |
中国医学 | 55篇 |
肿瘤学 | 3083篇 |
出版年
2023年 | 310篇 |
2022年 | 397篇 |
2021年 | 899篇 |
2020年 | 634篇 |
2019年 | 989篇 |
2018年 | 1155篇 |
2017年 | 882篇 |
2016年 | 906篇 |
2015年 | 1009篇 |
2014年 | 1419篇 |
2013年 | 2209篇 |
2012年 | 3207篇 |
2011年 | 3403篇 |
2010年 | 1805篇 |
2009年 | 1642篇 |
2008年 | 2941篇 |
2007年 | 2976篇 |
2006年 | 2892篇 |
2005年 | 2873篇 |
2004年 | 2631篇 |
2003年 | 2336篇 |
2002年 | 2240篇 |
2001年 | 346篇 |
2000年 | 299篇 |
1999年 | 378篇 |
1998年 | 484篇 |
1997年 | 374篇 |
1996年 | 286篇 |
1995年 | 249篇 |
1994年 | 247篇 |
1993年 | 237篇 |
1992年 | 204篇 |
1991年 | 193篇 |
1990年 | 154篇 |
1989年 | 159篇 |
1988年 | 124篇 |
1987年 | 133篇 |
1986年 | 128篇 |
1985年 | 134篇 |
1984年 | 134篇 |
1983年 | 107篇 |
1982年 | 110篇 |
1981年 | 114篇 |
1980年 | 85篇 |
1979年 | 61篇 |
1978年 | 49篇 |
1977年 | 49篇 |
1976年 | 46篇 |
1975年 | 39篇 |
1974年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
991.
Stability of Diagnoses of Cognitive Impairment,Not Dementia in a Veterans Affairs Primary Care Population 下载免费PDF全文
992.
Newly Developed Chronic Conditions and Changes in Health‐Related Quality of Life in Postmenopausal Women 下载免费PDF全文
993.
994.
Matias Trillini Monica Cortinovis Piero Ruggenenti Jorge Reyes Loaeza Karen Courville Claudia Ferrer-Siles Silvia Prandini Flavio Gaspari Antonio Cannata Alessandro Villa Annalisa Perna Eliana Gotti Maria Rosa Caruso Davide Martinetti Giuseppe Remuzzi Norberto Perico 《Journal of the American Society of Nephrology : JASN》2015,26(5):1205-1214
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 µg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8–152.0) to 63.3 (52.0–79.7) pg/ml (P<0.001) but not on nonparicalcitol therapy. At 6 months, levels significantly differed between treatments (P<0.001 by analysis of covariance). Serum bone-specific alkaline phosphatase and osteocalcin decreased on paricalcitol therapy only and significantly differed between treatments at 6 months (P<0.001 for all comparisons). At 6 months, urinary deoxypyridinoline-to-creatinine ratio and 24-hour proteinuria level decreased only on paricalcitol (P<0.05). L3 and L4 vertebral mineral bone density, assessed by dual-energy x-ray absorption, significantly improved with paricalcitol at 6 months (P<0.05 for both densities). Paricalcitol was well tolerated. Overall, 6-month paricalcitol supplementation reduced parathyroid hormone levels and proteinuria, attenuated bone remodeling and mineral loss, and reduced eGFR in renal transplant recipients with secondary hyperparathyroidism. Long-term studies are needed to monitor directly measured GFR, ensure that the bone remodeling and mineral effects are sustained, and determine if the reduction in proteinuria improves renal and cardiovascular outcomes. 相似文献
995.
Genotype–Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers 下载免费PDF全文
Soley Bayraktar MD MBA Michelle Jackson MS Angelica M. Gutierrez‐Barrera MS Diane Liu MS Funda Meric‐Bernstam MD Amanda Brandt MS Ashley Woodson MS Jennifer Litton MD Karen H. Lu MD Vicente Valero MD Banu K. Arun MD 《The breast journal》2015,21(3):260-267
The genotype–phenotype correlations of the specific BRCA1 and BRCA2 mutations in multi‐ethnic populations in USA have not yet been fully investigated. This study was designed to evaluate the effects of ethnicity at specific mutation locations and breast/ovarian cancer phenotypes. Our cohort included 445 women with different ethnic backgrounds who underwent BRCA genetic testing between 1997 and 2010. Known clinical and pathologic characteristics were compared with Chi‐Square Analysis or Fisher's Exact test as appropriate. The three most common mutation locations in BRCA1 (exons 2, 11, and 20) and BRCA2 (exons 10, 11, and 25) genes were chosen. Prevalence of BRCA1 exon 2 mutations were significantly higher in Ashkenazi Jewish (AJ) women compared to Caucasians (41% versus 15%; p = 0.001). Similarly, AJ women with breast cancer were more likely to have BRCA1 exon 2 mutation (47% positivity in AJ women versus 0–12.5% positivity in other ethnicities; p = 0.004). Women carrying the exon 20 BRCA1 mutation had the highest probability of having combined breast and ovarian cancers compared to women carrying other exon mutations (p = 0.05). The median age at initial cancer diagnosis, phenotypic features of breast cancer tumors, and overall survival did not vary significantly by ethnicity or mutation location. Our data suggest that ethnicity does not affect age of onset, overall survival or confer different risks of breast and ovarian cancer development in BRCA carriers. These results also suggest that women carrying the exon 20 BRCA1 mutation may warrant mutation‐specific counseling and be more aggressively managed for risk reduction. 相似文献
996.
997.
Piefel Karen Schneider Thomas Seegenschmiedt Michael Heinrich 《Trauma und Berufskrankheit》2015,18(3):246-253
Trauma und Berufskrankheit - Morbus Dupuytren (MD) und Morbus Ledderhose (ML) sind proliferative Bindegewebserkrankungen der Palmar- oder Plantaraponeurose. Zwei Drittel der Patienten weisen eine... 相似文献
998.
999.
Association of androgen‐deprivation therapy with excess cardiac‐specific mortality in men with prostate cancer 下载免费PDF全文
David R. Ziehr Ming‐Hui Chen Danjie Zhang Michelle H. Braccioforte Brian J. Moran Brandon A. Mahal Andrew S. Hyatt Shehzad S. Basaria Clair J. Beard Joshua A. Beckman Toni K. Choueiri Anthony V. D'Amico Karen E. Hoffman Jim C. Hu Neil E. Martin Christopher J. Sweeney Quoc‐Dien Trinh Paul L. Nguyen 《BJU international》2015,116(3):358-365
1000.
A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment 下载免费PDF全文
Nikesh Thiruchelvam Francesco Cruz Mike Kirby Andrea Tubaro Christopher R. Chapple Karl‐Dietrich Sievert 《BJU international》2015,116(6):853-861
There are various forms of treatment for prostate cancer. In addition to oncologic outcomes, physicians, and increasingly patients, are focusing on functional and adverse outcomes. Symptoms of overactive bladder (OAB), including urinary frequency, urgency and incontinence, can occur regardless of treatment modality. This article examines the prevalence, pathophysiology and options for treating OAB after radical prostate cancer treatment. OAB seems to be more common and severe after radiation therapy than after surgical therapy and even persisted longer with complications, suggesting an advantage for surgery over radiotherapy. Because OAB that occurs after radical prostate surgery or radiotherapy can be difficult to treat, it is important that patients are made aware of the potential development of OAB during counselling before decisions regarding treatment choice are made. To ensure a successful outcome of both treatments, it is imperative that clinicians and non‐specialists enquire about and document pretreatment urinary symptoms and carefully evaluate post‐treatment symptoms. 相似文献